Regenerative Medicine and Stem Cells Technologies

Waseda University researchers recently elucidated the regenerative processes of neural stem cells using a stab injury model in the optic tectum of adult zebrafish. The study could contribute to the treatment of human central nervous system (CNS) injuries.

A newly discovered type of stem cell could help brains repair themselves from injury or even debilitating diseases like Alzheimers, according to the latest research.

According to a new market research report "Stem Cell Assay Market by Type (Viability, Purification, Identification), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instruments, Kits), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 1,978.7 Million by 2023 from USD 791.9 Million in 2018, at a CAGR of 20.1%.

Stem cell therapy has produced impressive results in treating musculoskeletal conditions such as osteoarthritis and painful sprains and tears of muscles, ligaments and tendons. But harvesting stem cells from the body can be invasive and painful – is there an alternative? Yes, according to The Knee Institute and Regenerative Therapy, a clinic in West Bloomfield that uses only stem cells from human umbilical cords for the best results.

On Tuesday, a 13-year-old boy from New Jersey was at the center of medical history as he became the first person in the US to receive an FDA-approved gene therapy for an inherited disease. The event marks the beginning of a new era of medicine, one in which devastating genetic conditions that we are born with can be simply edited out of our DNA with the help of modern biomedical technologies.

Researchers from the Murdoch Childrens Research Institute (MCRI), University of Melbourne and Leiden University Medical Centre (LUMC) in The Netherlands have made an important step towards making human kidneys from stem cells that they one day hope can be used to treat kidney disease.

The regenerative capability of the central nervous system (CNS) is largely limited due to its intrinsic properties and external environment. Traditional thinking holds that once the brain is injured, it is impossible to repair and restore the tissue to normal. However, this notion has been challenged by a recent study.

TiGenix NV (Euronext Brussels and NASDAQ: TIG) ("TiGenix") and Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced that the European Commission (EC) has approved Alofisel (darvadstrocel), previously Cx601, for the treatment of complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohns disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula.[2] This marks the first allogeneic stem cell therapy to receive central marketing authorization (MA) approval in Europe.

A new report published by Bostons Institute for Clinical and Economic Review (ICER) concludes that two pricey new CAR-T cell therapies, Novartis AGs Kymriah (tisagenlecleucel) and Gilead Sciences Inc.s Yescarta (axicabtagene ciloleucel), both provided moderate certainty of a small to substantial net health benefit compared to commonly used chemotherapies or no therapy at all in their respective indications.

Time heals all wounds – or so the saying goes. But our ability to heal damaged organs or tissues, such as the skin, is by no means perfect and results in formation of a scar. Scars are more fragile and less elastic than undamaged skin, and they lack hair follicles, sebaceous glands and sweat glands as these do not regenerate. In particular, large wounds like those caused by burns can lead to serious functional and cosmetic impairments.